Analyst Ratings for Taysha Gene Therapies (TSHA)
TSHA Rating Summary
TSHA Price Target Summary
- Highest: $19.00 (Cantor Fitzgerald)
- Lowest: $10.00 (BofA Securities)
- Average: $13.60
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$13.60 (+275.7%)
* Over Last 12-Mos
Rating Score: 9 / 10
Percentile Rank: 89%
Avg. $ Target:
$13.60 (+275.7%)
* Over Last 12-Mos
Rating Score: 9 / 10
Percentile Rank: 89%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/17/2026 | Wolfe Research | Kalpit Patel | New Coverage | Outperform (N/A) |
N/A (N/A) |
5.08 (3.62) |
-28.74% | Details |
| 12/4/2025 | Goldman Sachs » Updated 7/21/2026 |
Salveen Richter | Upgrade | Buy (Early-Stage Biotech) |
13.00 (11.00) |
4.49 (3.62) |
-19.38% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
